>
BrightLearn - Revolutionizing Food: Grow Your Own Freedom...
VIDEO: Alex Jones Goes Off On Trump, "The Globalists Have Been Deliberately Destroying...
Menopause and gut health: Decoding the relationship between hormones and digestive issues
Magnetic Fields Reshape the Movement of Sound Waves in a Stunning Discovery
There are studies that have shown that there is a peptide that can completely regenerate nerves
Swedish startup unveils Starlink alternative - that Musk can't switch off
Video Games At 30,000 Feet? Starlink's Airline Rollout Is Making It Reality
Automating Pregnancy through Robot Surrogates
SpaceX launches Space Force's X-37B space plane on 8th mystery mission (video)
This New Bionic Knee Is Changing the Game for Lower Leg Amputees
Grok 4 Vending Machine Win, Stealth Grok 4 coding Leading to Possible AGI with Grok 5
Over the past year, the gap between the super-rich and the rest of us has grown wider than ever before.
But the difference between ordinary people and billionaires might be more than just money. Some high net worth individuals have been looking into extending their lives far beyond the 70 or 80 years most of us might hope for.
Peter Thiel, for example, the billionaire co-founder of PayPal, has invested in a number medical research start-ups looking extending life expectancy though his Breakout Labs fund.
One of the companies longevity obsessive Thiel has bankrolled is Ambrosia.
Ambrosia is one of three outfits looking at experimental "vampire" blood transfusions that put the blood of young people into the lens of oldies.
According to commercial finance experts ABC Finance, the cost of the trials currently ranges from £6,000 to about £215,000.